|
Patent landscape, scope, and claims: |
Scope and claims of US Patent 8,241,662 (ox ybutynin unoccluded topical gel targeting oxybutynin/N-desethyloxybutynin AUC ratio)
US 8,241,662 is a US method-of-treatment and formulation-use patent that claims once-daily, unoccluded topical oxybutynin gel for overactive bladder on specific body sites (chest/torso/abdomen/arms/thighs). The patent’s defining novelty is a pharmacokinetic exposure control metric: achieving a plasma AUC ratio of oxybutynin to its metabolite N-desethyloxybutynin (N-DEO) in a specified range (about 0.5:1 to about 5:1, with dependent claim subranges). This AUC ratio is tied to minimizing anticholinergic/antimuscarinic adverse drug experience. The claim body tightly enumerates gel composition ranges (water, gelling agent, high-alcohol solvent, optional emollient, optional pH additive, and optional permeation enhancer) and administration constraints (unoccluded, outer skin surface, once daily).
What does US 8,241,662 claim for oxybutynin overactive bladder gels?
Answer: A claimed treatment method where an unoccluded topical oxybutynin gel is applied once daily to specified outer-skin locations, using a gel formulation with defined component ranges and a pharmacokinetic target oxybutynin:N-desethyloxybutynin AUC ratio (about 0.5:1 to about 5:1), with an efficacy-safety linkage to minimizing anticholinergic/antimuscarinic adverse experience.
Core independent claim 1 (method + formulation parameterization + PK ratio)
Claim 1 is structured as:
- Condition/indication: overactive bladder
- Administration form: “unoccluded topical oxybutynin gel formulation”
- Route and dosing: topical application to outer skin surface, once a day
- Sites: chest, torso, abdomen, arms, or thighs
- Formulation composition constraints (required ranges and components):
- (i) therapeutically effective amount of oxybutynin free base and/or oxybutynin chloride
- (ii) water: about 1 wt % to about 30 wt %
- (iii) gelling agent: about 0.05 wt % to about 10 wt % chosen from a listed cellulose-derivative set
- (iv) solvent: at least 40 wt % from lower alcohols / C4–C10 mono-alcohols
- (v) optional emollient up to about 10 wt % from specified excipients
- (vi) optional pH additive from specified amines/acids/bases and salts
- (viii) optional permeation enhancer
- Pharmacokinetic exposure requirement: plasma AUC ratio of oxybutynin to N-desethyloxybutynin from about 0.5:1 to about 5:1
- Outcome linkage: “while minimizing an anticholinergic or antimuscarinic adverse drug experience”
Key technical effect embedded in claim scope: it is not just “a gel with oxybutynin.” It is a gel that produces a specific systemic metabolic exposure signature (oxybutynin relative to N-desethyloxybutynin) when applied topically under the claimed conditions.
Independent claim 5 (parallel scope phrased as oxybutynin administration to minimize adverse experience)
Claim 5 is effectively the same concept as claim 1, with the formulation constraint list re-stated and two main differences in structure:
- Claim 5 expresses the treatment as “method of treating … while minimizing an anticholinergic … adverse drug experience” and focuses on administering the gel to the outer skin surface.
- It sets the gelling agent as about 0.05 wt % to about 10 wt %, water about 1 wt % to about 30 wt %, solvent at least 40 wt %, optional permeation enhancer.
- It also includes the same AUC ratio constraint (about 0.5:1 to about 5:1).
How do claims 2–4 and 7–9 narrow the oxybutynin/N-desethyloxybutynin AUC ratio?
Answer: The patent provides multiple dependent claim “bands” for the oxybutynin:N-DEO AUC ratio, tightening the PK target in narrower ranges.
AUC ratio dependent claims
-
Claim 2 (depends on claim 1): AUC ratio 1:1 to 5:1
-
Claim 3 (depends on claim 1): 0.8:1 to 1.5:1
-
Claim 4 (depends on claim 1): 0.5:1 to 4:1
-
Claim 7 (depends on claim 5): 1:1 to 5:1
-
Claim 8 (depends on claim 5): 0.8:1 to 1.5:1
-
Claim 9 (depends on claim 5): 0.5:1 to 4:1
Enforceable interpretation impact
Because the PK ratio is an objective measured in plasma AUC, it becomes a central infringement pivot: a challenger can target whether the accused product/usage achieves the same AUC relationship under real administration conditions (site, unoccluded status, once-daily regimen, and formulation matrix). Dependent ranges create multiple ways to show a match (or a miss).
What formulation elements are explicitly required in US 8,241,662 claims?
Answer: A defined gel matrix with (a) limited water content, (b) specified gelling agent family at narrow wt % band, (c) high-alcohol solvent fraction, and (d) optional emollients, pH additives, and permeation enhancers.
Required composition ranges in claims 1 and 5
| Component |
Requirement (claims 1/5) |
Chemical/excipient scope |
| Oxybutynin active |
“therapeutically effective amount” |
oxybutynin free base and/or oxybutynin chloride |
| Water |
~1–30 wt % |
implicit “water” phase content |
| Gelling agent |
~0.05–10 wt % |
listed cellulose derivatives (hydroxypropyl cellulose and analogs; ethylcellulose; carboxymethyl cellulose; hydroxypropylmethyl cellulose phthalate; cellulose acetate; and mixtures/copolymers) |
| Solvent |
≥40 wt % |
lower alcohols and/or C4–C10 mono-alcohols |
| Emollient |
optional up to ~10 wt % |
fatty alcohols (C12–C20), fatty acid esters (C12–C20), petrolatum, mineral oils, oils, aloe vera gel, glycerol, allantoin |
| pH additive |
optional |
amines, alkanolamines, acids/salts, hydroxides |
| Permeation enhancer |
optional |
fatty acids/esters, fatty alcohols, lactic/glycolic esters, glycerol esters, triacetin, short chain alcohols |
Administration constraints that affect scope
| Constraint |
Claim language effect |
| Unoccluded topical gel |
excludes covered/occluded application configurations |
| Outer skin surface |
requires topical contact to skin, not intradermal or mucosal routes |
| Once a day |
dosing regimen constraint |
| Sites |
limits to chest, torso, abdomen, arms, thighs (and dependent “area” formulations) |
How do dependent claims 6, 10–18 narrow the composition and use scenarios?
Answer: Dependent claims further specify solvent level, dosing sites, alcohol selection (ethanol and others), and a specific example formulation archetype (oxybutynin chloride + hydroxypropyl cellulose + ethanol + glycerol + sodium hydroxide).
Solvent level tightening
- Claim 6 (depends on claim 5): solvent present in an amount of at least ~70 wt %
This is a material narrowing relative to the independent “at least 40 wt %” requirement.
Application area narrowing
- Claim 10 (depends on claim 5): application area from chest, torso, abdomen, arm, thigh and combinations
This is mostly confirming and does not add new sites beyond the independent claim set.
Solvent alcohol identity
- Claim 11: lower alcohol/C4–C10 mono-alcohol selected from ethanol, isopropanol, benzyl alcohol, propanol, methanol, mixtures
- Claim 12: solvent is ethanol
- Claim 13: repeats Claim 11 scope in the claim 5 dependence chain
- Claim 14: repeats Claim 12 (ethanol)
A “worked” formulation example as a dependent claim
- Claim 15: oxybutynin is oxybutynin chloride; gelling agent hydroxypropyl cellulose; solvent ethanol; emollient glycerol; pH additive sodium hydroxide
- Claim 16: oxybutynin chloride + hydroxypropyl cellulose (partial narrowing; leaves other formulation elements variable within the independent ranges)
Permeation enhancer families
- Claim 17 and Claim 18: permeation enhancer selected from fatty acids, fatty acid esters, fatty alcohols, lactic/glycolic esters, glycerol esters, triacetin, short chain alcohols (and mixtures). Claims 17 and 18 repeat the same list with different dependency context.
What is the practical scope of infringement risk under a PK-ratio claim structure?
Answer: The core infringement issue is whether an accused topical oxybutynin gel, when used under unoccluded once-daily conditions on the claimed skin areas, yields an oxybutynin:N-desethyloxybutynin AUC ratio in the claimed range.
Why the AUC ratio is a litigation-critical element
- It converts a formulation claim into a “performance” constraint.
- It is measurable using pharmacokinetic studies.
- It can shift infringement from “ingredient match” to “systemic exposure match.”
Common risk paths for generic or “follow-on” products
A follow-on gel that uses different gelling agents, different alcohol/solvent splits, or different enhancer systems can still fall in if it achieves the same AUC ratio. Conversely, a gel that matches ingredient ranges but produces a different metabolite exposure balance could avoid the claim.
Unoccluded and once-daily constraints as usage limitations
Even if formulation composition is very similar, infringement can hinge on:
- whether the product is used unoccluded (no bandage/dressing over the gel),
- whether it is dosed once daily, and
- whether application is to the claimed skin regions.
How strong is the patent estate likely to be based on the claim’s structure?
Answer: Strength is concentrated in the PK-ratio element plus the detailed excipient universe and wt % ranges. A challenger must attack either (a) validity (if the PK target and composition were not new/nonobvious over the prior art) or (b) infringement (if the alleged product does not achieve the AUC ratio).
Strength drivers embedded in the claims
- Specific metabolite ratio target: oxybutynin vs N-desethyloxybutynin is a narrow pharmacokinetic framing rather than a broad “improve tolerability” assertion.
- Broad excipient lists but narrow “quantitative fences”: water and gelling agent wt % ranges and solvent fraction are fixed.
- Explicit unoccluded and site limits: reduces some interpretive breadth.
Attack surface embedded in the claims
- “Minimizing adverse experience” is a functional statement. The claims still anchor on the AUC ratio, which is more objective.
- If prior art discloses gels with similar composition and known metabolite relationships, the novelty and nonobviousness analysis may be contested. The claim’s performance metric can be argued as inherent or predictable depending on the prior art record.
What patent landscape questions are answerable from the claim set alone?
Answer: The provided claim text supports only a partial landscape assessment. It allows mapping of claim boundaries but does not provide:
- priority/application dates,
- patent term adjustments,
- continuation history,
- prosecution history,
- related family members,
- other US patents covering the same gel (e.g., specific manufacturing methods or additional PK windows),
- Orange Book listings for branded oxybutynin products,
- or any Paragraph IV/ITC litigation record.
Because those are not supplied, no definitive expiration timeline, exclusivity status, or litigation mapping can be generated.
Claim-by-claim scope matrix (what must be present for infringement)
Answer: Below is an infringement checklist keyed to each claim.
Independent claim 1 infringement checklist
- Patient with overactive bladder
- Method includes once-daily topical application
- Unoccluded topical gel on outer skin surface
- Application to chest/torso/abdomen/arms/thighs
- Gel composition meets:
- oxybutynin free base and/or oxybutynin chloride,
- water ~1–30 wt %,
- gelling agent ~0.05–10 wt % from listed cellulose-derivative group,
- solvent ≥40 wt % from lower alcohols/C4–C10 mono-alcohols,
- optional emollient (≤~10 wt %), optional pH additive, optional permeation enhancer
- Achieves plasma AUC (oxybutynin) / AUC (N-desethyloxybutynin) of ~0.5:1 to ~5:1
- Treatment is described as minimizing anticholinergic/antimuscarinic adverse experience
Dependent claim deltas
- Claims 2–4: AUC ratio narrowed to specified bands.
- Claims 5–9: same as claim 1 concept but with independent claim 5’s restatement and dependent narrowing.
- Claim 6: solvent ≥~70 wt %.
- Claim 10: site enumerations limited to defined set (already included in claim 1).
- Claims 11–14: alcohol selection specific sets including ethanol.
- Claims 15–16: specific exemplar formulation selections (oxybutynin chloride + hydroxypropyl cellulose + ethanol + glycerol + sodium hydroxide; plus a partial variant).
- Claims 17–18: permeation enhancer selection restricted to stated families.
Key Takeaways
- US 8,241,662 is centered on a topical unoccluded oxybutynin gel regimen for overactive bladder using defined gel composition ranges plus a plasma PK constraint: oxybutynin:N-desethyloxybutynin AUC ratio ~0.5:1 to ~5:1.
- Dependent claims tighten the PK band (1:1–5:1; 0.8:1–1.5:1; 0.5:1–4:1) and further fence formulation variables, including solvent loading (≥~70 wt %) and solvent identity (ethanol).
- Infringement is performance-sensitive due to the AUC ratio requirement, making clinical PK evidence and real-world usage conditions (unoccluded, once daily, application site) central.
- The claim text alone does not support a complete US exclusivity/expiration or litigation/Orange Book landscape without external records.
FAQs
-
Can a generic oxybutynin gel avoid infringement by changing only the permeation enhancer?
If it still matches the claimed composition ranges and achieves the oxybutynin:N-desethyloxybutynin AUC ratio band under unoccluded once-daily use, it can remain within scope even with different enhancer chemistry, because the PK ratio is the performance anchor.
-
What happens if an accused product uses the same ingredients but is applied under occlusion?
Occluded use can fall outside the “unoccluded topical” limitation, creating a usage-based noninfringement path even if the formulation is similar.
-
Does the patent require ethanol specifically?
No. Ethanol is a dependent-claim solvent option, not an independent requirement. Independent claims allow lower alcohols/C4–C10 mono-alcohols broadly, provided the solvent fraction and PK ratio constraints are met.
-
Is the “minimizing adverse experience” element an objective requirement?
The claim wording ties tolerability to the treatment and constrains the method using an objective pharmacokinetic ratio. The tolerability language functions as a described clinical outcome while the AUC ratio provides a measurable proxy in the claim language.
-
Do the claims cover both oxybutynin free base and oxybutynin chloride?
Yes. The independent claim recites either or a mixture, and dependent claim 15 specifies oxybutynin chloride for the example formulation.
References (APA)
- US Patent 8,241,662, “Methods of treatment using unoccluded topical oxybutynin gel formulations,” claims text provided.
More… ↓
⤷ Start Trial
|
